National Pension Service Decreases Stake in Illumina, Inc. (NASDAQ:ILMN)

National Pension Service lessened its stake in Illumina, Inc. (NASDAQ:ILMN) by 11.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 265,123 shares of the life sciences company’s stock after selling 35,538 shares during the quarter. National Pension Service’s holdings in Illumina were worth $35,428,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Versant Capital Management Inc lifted its stake in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 146 shares during the last quarter. Golden State Wealth Management LLC purchased a new stake in Illumina during the fourth quarter worth approximately $32,000. TD Private Client Wealth LLC lifted its stake in Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares during the last quarter. V Square Quantitative Management LLC lifted its stake in Illumina by 50.6% during the fourth quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 132 shares during the last quarter. Finally, First Horizon Advisors Inc. lifted its stake in Illumina by 73.5% during the fourth quarter. First Horizon Advisors Inc. now owns 439 shares of the life sciences company’s stock worth $59,000 after purchasing an additional 186 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 0.3 %

Shares of ILMN stock opened at $88.74 on Friday. The business’s fifty day moving average price is $123.38 and its 200 day moving average price is $132.96. Illumina, Inc. has a 1-year low of $87.50 and a 1-year high of $156.66. The firm has a market capitalization of $14.06 billion, a PE ratio of -11.55, a P/E/G ratio of 1.60 and a beta of 1.10. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ILMN shares. Royal Bank of Canada decreased their target price on Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Canaccord Genuity Group decreased their target price on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday, February 7th. Stephens boosted their target price on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Guggenheim cut their price target on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. lifted their price target on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and an average price target of $155.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.